ADA Advises Wider Use of Newer Glucose-Lowering Drugs ADA Advises Wider Use of Newer Glucose-Lowering Drugs

In the 2020 Standards of Care, the American Diabetes Association advises consideration of SGLT2 inhibitors and GLP-1 receptor agonists in patients with high CVD or renal risk, regardless of A1c.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news